Allarity dosed second patient in new Phase 2 stenoparib trial for advanced ovarian cancer

Allarity Therapeutics, Inc.

Second patient dosed in new Phase 2 trial of stenoparib for advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
CEO Thomas Jensen cited strong investigator engagement and rapid enrollment pace.
Trial builds on prior Phase 2 data showing durable benefit and favorable tolerability with twice-daily dosing.
Stenoparib is a dual PARP and WNT pathway inhibitor; trial also advances DRP companion diagnostic.
Current platinum-resistant patients have limited treatment options; stenoparib aims to offer a better-tolerated alternative.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.